Vis enkel innførsel

Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition

dc.contributor.authorBrumpton, Ben Michael
dc.contributor.authorFritsche, Lars
dc.contributor.authorZheng, Jie
dc.contributor.authorNielsen, Jonas Bille
dc.contributor.authorMannila, Maria Nastase
dc.contributor.authorSurakka, Ida
dc.contributor.authorRasheed, Humaira
dc.contributor.authorVie, Gunnhild Åberge
dc.contributor.authorGraham, Sarah E.
dc.contributor.authorGabrielsen, Maiken Elvestad
dc.contributor.authorLaugsand, Lars Erik
dc.contributor.authorAukrust, Pål
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorDamås, Jan Kristian
dc.contributor.authorUeland, Thor
dc.contributor.authorJanszky, Imre
dc.contributor.authorZwart, John-Anker
dc.contributor.authorvan't Hooft, Ferdinand M.
dc.contributor.authorSeidah, Nabil Georges
dc.contributor.authorHveem, Kristian
dc.contributor.authorWiller, Cristen
dc.contributor.authorSmith, George Davey
dc.contributor.authorÅsvold, Bjørn Olav
dc.date.accessioned2020-03-23T08:39:40Z
dc.date.available2020-03-23T08:39:40Z
dc.date.created2019-04-27T13:21:40Z
dc.date.issued2019
dc.identifier.issn2574-8300
dc.identifier.urihttps://hdl.handle.net/11250/2648012
dc.description.abstractPCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 inhibition.en_US
dc.language.isoengen_US
dc.publisherAmerican Heart Associationen_US
dc.titleVariation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibitionen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.source.volume12en_US
dc.source.journalCirculation. Genomic and precision medicineen_US
dc.source.issue1en_US
dc.identifier.doi10.1161/CIRCGEN.118.002335
dc.identifier.cristin1694350
dc.relation.projectNorges forskningsråd: 248817en_US
dc.relation.projectNorges forskningsråd: 299113en_US
dc.relation.projectStiftelsen Kristian Gerhard Jebsen: SKGJ-MED-015en_US
dc.relation.projectNorges forskningsråd: 250335en_US
dc.description.localcode© 2019. This is the authors' accepted and refereed manuscript to the article. The final authenticated version is available online at: http://dx.doi.org/10.1161/CIRCGEN.118.002335en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail
Filnavn:
Brumpton.pdf
Størrelse:
888.5Kb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel